2019
Hippocampal Subfields in Acute and Remitted Depression—an Ultra-High Field Magnetic Resonance Imaging Study
Kraus C, Seiger R, Pfabigan D, Sladky R, Tik M, Paul K, Woletz M, Gryglewski G, Vanicek T, Komorowski A, Kasper S, Lamm C, Windischberger C, Lanzenberger R. Hippocampal Subfields in Acute and Remitted Depression—an Ultra-High Field Magnetic Resonance Imaging Study. The International Journal Of Neuropsychopharmacology 2019, 22: 513-522. PMID: 31175352, PMCID: PMC6672627, DOI: 10.1093/ijnp/pyz030.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAffectAntidepressive Agents, Second-GenerationAustriaCitalopramDepressive Disorder, MajorDrug SubstitutionFemaleHippocampusHumansMagnetic Resonance ImagingMaleMiddle AgedPredictive Value of TestsRemission InductionSelective Serotonin Reuptake InhibitorsSerotonin and Noradrenaline Reuptake InhibitorsTreatment OutcomeVenlafaxine HydrochlorideYoung AdultConceptsMajor depressive disorderDepressive disorderHippocampal subfieldsSubfield volumesAntidepressant treatmentHealthy controlsHippocampal-amygdaloid transition areaMajor depressive disorder patientsOpen-label studyMagnetic resonance imaging studyDepressive disorder patientsHippocampal formation volumeStructural magnetic resonance imagingHippocampal volume changesLower baseline volumesTreatment-related changesResonance imaging studyMagnetic resonance imagingMeasurement time pointsSerotonergic antidepressantsWeeks treatmentAcute patientsRight subiculumUnmedicated patientsBaseline volume
2018
Structural changes in amygdala nuclei, hippocampal subfields and cortical thickness following electroconvulsive therapy in treatment-resistant depression: longitudinal analysis
Gryglewski G, Baldinger-Melich P, Seiger R, Godbersen GM, Michenthaler P, Klöbl M, Spurny B, Kautzky A, Vanicek T, Kasper S, Frey R, Lanzenberger R. Structural changes in amygdala nuclei, hippocampal subfields and cortical thickness following electroconvulsive therapy in treatment-resistant depression: longitudinal analysis. The British Journal Of Psychiatry 2018, 214: 159-167. PMID: 30442205, PMCID: PMC6383756, DOI: 10.1192/bjp.2018.224.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionElectroconvulsive therapyMagnetic resonance imagingCortical thicknessHippocampal subfieldsAmygdala nucleiHippocampal-amygdaloid transition areaRight unilateral electroconvulsive therapyEffects of ECTHigh-resolution structural magnetic resonance imagingUnipolar treatment-resistant depressionCorticoamygdaloid transition areaPathophysiology of depressionPre-post study designCorrelation of imagingUnilateral electroconvulsive therapyTreatment of choiceStructural magnetic resonance imagingSpecific hippocampal subfieldsSevere mental illnessGrant/research supportStress-related disordersClinical parametersRepeated-measures ANOVADentate gyrusBrain monoamine oxidase A in seasonal affective disorder and treatment with bright light therapy
Spies M, James GM, Vraka C, Philippe C, Hienert M, Gryglewski G, Komorowski A, Kautzky A, Silberbauer L, Pichler V, Kranz GS, Nics L, Balber T, Baldinger-Melich P, Vanicek T, Spurny B, Winkler-Pjrek E, Wadsak W, Mitterhauser M, Hacker M, Kasper S, Lanzenberger R, Winkler D. Brain monoamine oxidase A in seasonal affective disorder and treatment with bright light therapy. Translational Psychiatry 2018, 8: 198. PMID: 30242221, PMCID: PMC6155094, DOI: 10.1038/s41398-018-0227-2.Peer-Reviewed Original ResearchConceptsBright light therapyMAO-A levelsBrain MAO-A levelsSeasonal affective disorderPositron emission tomographyMAO-A VTNon-seasonal depressionHealthy controlsLight therapyAffective disordersTreatment of SADMajor depressive disorderBrain monoamine oxidaseCerebral MAODepressive disorderSerotonergic systemPET scansHC groupMilder symptomsPatientsDistribution volumeEmission tomographyMonoamine oxidaseDisordersSignificant reduction